Abstract: Progress in targeted therapy for HER-2 positive breast cancer        WANG  Yang , QU  Xiang. Department of General Surgery，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China
Corresponding author:QU Xiang，E-mail：cqx3968@sina.com
Abstract    The treatment for human epidermal growth factor receptor-2（HER-2） positive breast cancer has always been highlighted in the research field of breast cancer. Anti-HER-2 targeted therapy was the standard treatment for HER-2-positive breast cancer. The application of monoclonal antibody, such as trastuzumab, has significant improved the prognosis of HER-2 positive breast cancer patients. Additionally, researches on noval HER-2 targeted drugs including mAbs (eg.Pertuzumab), small-molecular tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs) have made rapid progressions, showing great clinical prospects in the aspects of adjuvant therapy, neoadjuvant therapy and therapy for advanced breast cancer, which will help to further improve the efficacy of HER-2 positive breast cancer.

Key words: human epidermal growth factor receptor-2, targeted therapy, antibody-drug conjugate, tyrosine kinase inhibitors, neoadjuvant therapy

摘要： 人类表皮生长因子受体-2（HER-2）阳性乳腺癌的诊治近年来一直是乳腺癌领域的研究热点，抗HER-2靶向治疗是HER-2阳性乳腺癌的标准治疗手段，单克隆抗体类靶向药物曲妥珠单克隆抗体的临床应用显著改善了HER-2阳性乳腺癌病人的预后。此外同类型靶向药物帕妥珠单克隆抗体、小分子靶向药物酪氨酸激酶抑制剂、抗体⁃药物偶联物等抗HER-2新药的相关研究也进展迅速，无论在辅助治疗、新辅助治疗还是晚期乳腺癌治疗方面均显示了巨大的临床应用前景，有助于进一步提升HER-2阳性乳腺癌病人的疗效。

关键词: 人类表皮生长因子受体-2, 靶向治疗, 抗体药物偶联物, 酪氨酸激酶抑制剂, 新辅助治疗